Tag: cardiology research
-
DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation
New Findings Question SGLT2 Inhibitors for Post-Ablation AF Recurrence In a development that surprises many in the cardiology community, the DARE-HF trial examined whether the SGLT2 inhibitor dapagliflozin could reduce the burden of atrial fibrillation (AF) after catheter ablation. Conducted in patients who recently underwent ablation for AF, the study aimed to determine if adding…
-
Stopping DOACs After Successful AF Ablation: Feasible in Low-Risk Patients? Insights from OCEAN Trial
New Evidence Questions Long-Term Anticoagulation After AF Ablation For patients with atrial fibrillation (AF) who undergo successful ablation, clinicians often face the question: should a patient continue taking a direct oral anticoagulant (DOAC) or switch to an antiplatelet strategy like aspirin? The OCEAN trial, presented in New Orleans, Louisiana, provides new data suggesting that, among…